<DOC>
	<DOCNO>NCT01936181</DOCNO>
	<brief_summary>This randomize , double-blind , parallel group , multicentre clinical study evaluate efficacy , safety , pharmacokinetics immunogenicity SB2 compare Remicade subject moderate severe Rheumatoid Arthritis ( RA ) despite Methotrexate ( MTX ) therapy .</brief_summary>
	<brief_title>A Study Comparing SB2 Remicade® Subjects With Moderate Severe Rheumatoid Arthritis Despite Methotrexate Therapy</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Diagnosed RA accord revised 1987 ACR criterion least 6 month Have moderate severe active disease despite MTX therapy define equal six swollen joint equal six tender joint either erythrocyte sedimentation rate ( ESR , Westergren ) ≥ 28 mm/h serum Creactive protein ≥ 1.0 mg/dL Must treat MTX least 6 month prior Randomisation stable dose MTX 1025 mg/week give least 4 week prior Screening Female subject pregnant nursing Screening plan become pregnant Screening 6 month last dose investigational product Inclusion Criteria TransitionExtension Period : Have enrol complete schedule Week 54 visit randomise , doubleblind period SB2G31RA study In opinion Investigator , subject may benefit continue IP treatment ( either SB2 Remicade ) , understand implication take part study willing participate transitionextension period Have treat previously biological agent include tumour necrosis factor inhibitor Have know hypersensitivity human immunoglobulin proteins component Remicade SB2 Have positive serological test hepatitis B hepatitis C know history infection human immunodeficiency virus Have current diagnosis active tuberculosis Have serious infection treat intravenous antibiotic infection within 8 week oral antibiotic within 2 week prior Randomisation . Have follow condition 1 . Other inflammatory rheumatic disease . 2 . History malignancy within previous 5 year prior Screening 3 . History lymphoproliferative disease include lymphoma . 4 . History congestive heart failure 5 . Physical incapacitation ( ACR functional Class IV wheelchair/bedbound ) . 6 . History demyelinate disorder . Exclusion Criteria TransitionExtension Period : Have withdraw SB2G31RA study reason Have significant medical condition , occurrence serious AE ( SAE ) intolerance SB2 Remicade randomise , doubleblind period SB2G31RA study may render subject unsuitable participate transitionextension period , discretion Investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>Infliximab</keyword>
	<keyword>Biosimilar</keyword>
</DOC>